The FDA has approved Pfizer's cancer drug Sutent for advanced kidney cancer and a rare stomach cancer, according to a report in The Wall Street Journal. Pfizer says it expects to make the drug available February 3, with a six-week regimen of the therapy costing $4,000 and an annual supply priced at $38,000.
- read this AFX report [1] for more information
PLUS: As of late Friday morning Pfizer was still awaiting final word from the FDA on the fate of Exubera. Report [2]
Links:
[1] http://www.forbes.com/home/feeds/afx/2006/01/27/afx2481352.html
[2] http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=OBR&Date=20060127&ID=5453358